Rosewind Corporation — Form 10-Q Summary
Business context and reporting period
The filing is for Rosewind Corporation, described as a development-stage sailing-school business, for the quarter and six months ended February 29, 2012. This does not match the request metadata identifying Aytu Biopharma; verify the issuer and filing before relying on this summary. The company reported only $1,750 of revenue since inception and said it had collected full tuition from one student.
Financial results and position
- Revenue: None in the three or six months ended February 29, 2012; inception-to-date revenue was $1,750.
- Expenses and loss: Six-month operating expenses were $28,099, versus $42,864 in the prior-year period. Six-month net loss was $29,746, versus $44,550; quarterly net loss was $10,079, versus $26,835.
- Margins: Not meaningful given no current-period revenue.
- Cash flow: Operating activities used $19,380 over six months. Financing provided $16,235, including $13,487 from common-stock issuances and $3,748 in related-party loans. Ending cash was $848, down from $3,993 at August 31, 2011.
- Liquidity and debt: Current assets were $1,001 and current liabilities $65,742, producing a $64,741 working-capital deficit. Related-party loans payable were $55,048, secured by the vessel, bearing 6% interest and due on demand; accrued related-party interest was $6,797.
- Equity: Shareholders’ deficit was $49,454. The company issued 79,910 shares for $11,987 cash during the six months and received $1,500 for a share subscription; 10,000 subscription shares were issued after quarter-end.
Material changes versus prior period
Six-month net loss declined by $14,804, or 33%, year over year. Management attributed the improvement mainly to lower boat repair and maintenance and management expenses, which fell by $16,266, or 75%, to $5,515; it said the yacht was docked and not in use during the entire second quarter. Cash fell by $3,145 from fiscal year-end, while accounts payable and related-party borrowing increased.
Outlook, risks and unusual items
- Management said continued operations depend on generating cash and ultimately achieving profitability; it planned to seek additional equity funding but gave no assurance it could raise funds.
- The filing states that available cash was estimated to sustain the business for a maximum of two months from the report date. It also identifies going-concern uncertainty, operating losses since inception, unproven demand, and substantial additional funding needs.
- Risks include vessel maintenance and safety, limited insurance, possible licensing or regulatory requirements, dependence on key personnel, and the niche nature of the sailing-school market. The filing says the captain, who is the president’s son, would not be available for maintenance or training for the foreseeable future.
- No revenue or earnings guidance is provided. Results for the six months are expressly stated not to be necessarily indicative of full-year results.
- Management reported disclosure controls as effective and no material changes to internal control over financial reporting.
Most important facts to verify
- Confirm the filing belongs to the intended company: its cover and financial statements identify Rosewind Corporation, not Aytu Biopharma.
- Reconcile the filing’s vessel-location disclosures: it identifies the vessel as being in Port Townsend, Washington, while other risk text discusses recovery of a vessel located abroad.
- Review the going-concern disclosure, the two-month cash runway estimate, and the company’s ability to secure financing or generate student revenue.
- Confirm the related-party loan terms, demand status, collateral, accrued interest, and subsequent issuance of the 10,000 subscription shares.
- Assess the filing’s inconsistent statements about applicable vessel licensing and certification requirements, and the extent of insurance coverage.